{"hands_on_practices": [{"introduction": "To understand the molecular basis of addiction, we must first model how drugs of abuse alter the dynamics of neurotransmitters in the reward pathway. This practice challenges you to work with a mathematical model of extracellular dopamine concentration to predict how two different psychostimulants, cocaine and amphetamine, produce distinct neurochemical signatures. By analyzing their unique effects on the dopamine transporter, you will connect drug pharmacology to the dynamic signals measured by techniques like fast-scan cyclic voltammetry (FSCV), a critical skill for interpreting experimental data. [@problem_id:2728176]", "problem": "Fast-scan cyclic voltammetry (FSCV) measures extracellular dopamine concentration dynamics in nucleus accumbens tissue with subsecond resolution. Consider a simplified mass-balance for extracellular dopamine concentration $C(t)$:\n$$\n\\frac{dC}{dt} \\;=\\; R_{\\mathrm{ves}}(t) \\;+\\; J_{\\mathrm{rev}} \\;-\\; U(C),\n$$\nwhere $R_{\\mathrm{ves}}(t)$ is a transient vesicular release term evoked by brief electrical stimulation, $J_{\\mathrm{rev}}$ is a tonic non-vesicular efflux term mediated by transporter reversal, and $U(C)$ is dopamine uptake by the dopamine transporter (DAT) well approximated by Michaelis–Menten kinetics,\n$$\nU(C) \\;=\\; \\frac{V_{\\max}\\, C}{K_m + C}.\n$$\nAssume the following drug mechanisms grounded in standard transporter biophysics:\n- Cocaine acts as a competitive inhibitor of DAT. In the presence of inhibitor concentration $[I]$ with inhibition constant $K_i$, the apparent Michaelis–Menten constant is $K_m' \\,=\\, K_m \\left(1 + \\frac{[I]}{K_i}\\right)$ while $V_{\\max}$ for uptake remains unchanged. Cocaine does not directly drive reverse transport, so $J_{\\mathrm{rev}} \\approx 0$.\n- Amphetamine is a DAT substrate that promotes reverse transport. It increases $J_{\\mathrm{rev}} \\,>\\, 0$ and competes for uptake, effectively reducing net dopamine clearance at a given $C$. In addition, by collapsing vesicular pH gradients and engaging vesicular monoamine transporter $2$ (VMAT2), it reduces the readily releasable vesicular dopamine pool over short timescales, so the effective $R_{\\mathrm{ves}}(t)$ amplitude decreases across repeated stimuli.\n\nYou apply a single brief electrical stimulus that evokes a stereotyped $R_{\\mathrm{ves}}(t)$ in control solution, producing a dopamine transient in FSCV with a rapid rising phase and a mono-exponential-like decay governed primarily by DAT. You then switch to either cocaine or amphetamine at transporter-occupying concentrations and evoke an otherwise identical stimulus. Background subtraction in FSCV removes slowly varying currents on the scale of the voltammetric scan but preserves phasic deviations around the local baseline.\n\nWhich option best predicts the qualitative differences you would observe in the FSCV signals between cocaine and amphetamine, based on the governing equation and the drug mechanisms above?\n\nA. Cocaine: baseline extracellular dopamine remains near zero between stimuli, the evoked peak is larger and the decay is slower, increasing the area under the curve. Amphetamine: the baseline extracellular dopamine is elevated prior to stimulation, the evoked peak relative to baseline is reduced and can progressively diminish with repeated stimuli, and the decay is slower with a broadened transient.\n\nB. Cocaine: baseline extracellular dopamine shows a marked tonic elevation due to increased non-vesicular release, the evoked peak is reduced, and the decay is faster. Amphetamine: baseline remains near zero, the evoked peak is larger due to uptake inhibition, and the decay is unchanged.\n\nC. Cocaine: because uptake becomes saturated, the evoked transient decays faster to baseline with a smaller area under the curve, while baseline remains near zero. Amphetamine: reverse transport has no effect on baseline, but the evoked peak is greatly increased with a faster decay due to transporter cycling.\n\nD. Cocaine: uptake inhibition prolongs the rise time, yielding a slower and smaller peak with no change in decay, and it elevates baseline substantially. Amphetamine: reverse transport accelerates clearance, shortening the decay time, and it increases the evoked peak amplitude because more dopamine is expelled during exocytosis.\n\nChoose the single best option.", "solution": "The problem statement is critically validated before proceeding to a solution.\n\n### Step 1: Extract Givens\nThe problem provides the following information:\n1.  A simplified mass-balance equation for extracellular dopamine concentration $C(t)$:\n    $$\n    \\frac{dC}{dt} \\;=\\; R_{\\mathrm{ves}}(t) \\;+\\; J_{\\mathrm{rev}} \\;-\\; U(C)\n    $$\n2.  Definitions of the terms:\n    -   $R_{\\mathrm{ves}}(t)$: transient vesicular release evoked by electrical stimulation.\n    -   $J_{\\mathrm{rev}}$: tonic non-vesicular efflux mediated by transporter reversal.\n    -   $U(C)$: dopamine uptake by the dopamine transporter (DAT), following Michaelis–Menten kinetics:\n        $$\n        U(C) \\;=\\; \\frac{V_{\\max}\\, C}{K_m + C}\n        $$\n3.  Mechanisms of cocaine:\n    -   Acts as a competitive inhibitor of DAT.\n    -   The apparent Michaelis–Menten constant becomes $K_m' \\,=\\, K_m \\left(1 + \\frac{[I]}{K_i}\\right)$, where $[I]$ is inhibitor concentration and $K_i$ is the inhibition constant.\n    -   $V_{\\max}$ for uptake remains unchanged.\n    -   Cocaine does not directly drive reverse transport, so $J_{\\mathrm{rev}} \\approx 0$.\n4.  Mechanisms of amphetamine:\n    -   Is a DAT substrate that promotes reverse transport, increasing $J_{\\mathrm{rev}} > 0$.\n    -   Competes for uptake, reducing net dopamine clearance.\n    -   Reduces the readily releasable vesicular dopamine pool by interacting with vesicular monoamine transporter 2 (VMAT2), decreasing the effective $R_{\\mathrm{ves}}(t)$ amplitude across repeated stimuli.\n5.  Experimental context:\n    -   A single brief electrical stimulus evokes a stereotyped $R_{\\mathrm{ves}}(t)$.\n    -   Fast-scan cyclic voltammetry (FSCV) measures $C(t)$ dynamics with subsecond resolution.\n    -   FSCV background subtraction removes slowly varying signals but preserves phasic deviations around the local baseline.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded:** The problem is based on a standard and well-accepted mass-balance model for neurotransmitter dynamics. The use of Michaelis–Menten kinetics for transporter function is a fundamental concept in biochemistry and neuropharmacology. The described mechanisms of cocaine as a competitive DAT inhibitor and amphetamine as a DAT substrate/releaser are cornerstones of addiction neuroscience. The experimental technique (FSCV) is accurately described. The problem is firmly rooted in established scientific principles of cellular and molecular neuroscience.\n-   **Well-Posed:** The problem presents a clear mathematical framework and asks for qualitative predictions based on specified changes to the model parameters. The question is unambiguous and allows for a unique, reasoned answer to be derived from the given information.\n-   **Objective:** The problem is stated in precise, technical language. The drug mechanisms are defined through their effects on specific terms in the governing equation ($K_m$, $J_{\\mathrm{rev}}$, $R_{\\mathrm{ves}}(t)$), avoiding subjective or ambiguous descriptions.\n-   The problem is self-contained, consistent, and does not exhibit any of the flaws listed in the validation criteria (e.g., it is not incomplete, contradictory, unrealistic, or trivial).\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution can be derived.\n\n### Derivation of the Solution\nWe analyze the behavior of the dopamine concentration $C(t)$ under three conditions: control, cocaine, and amphetamine, based on the governing equation $\\frac{dC}{dt} = R_{\\mathrm{ves}}(t) + J_{\\mathrm{rev}} - U(C)$.\n\n**1. Control Condition**\n-   **Baseline:** In the absence of stimulation ($R_{\\mathrm{ves}}(t) = 0$) and assuming negligible basal reverse transport ($J_{\\mathrm{rev}} \\approx 0$), the steady-state concentration $C_{ss}$ is found by setting $\\frac{dC}{dt}=0$. This gives $0 = 0 - U(C_{ss})$, which requires $U(C_{ss}) = 0$. For the given Michaelis-Menten form of $U(C)$, this implies $C_{ss} = 0$. Thus, baseline dopamine is near zero.\n-   **Evoked Transient:** A brief stimulus provides a pulsatile release $R_{\\mathrm{ves}}(t) > 0$, causing $C(t)$ to rise. After the release ends, the decay is governed by $\\frac{dC}{dt} = -U(C) = -\\frac{V_{\\max}C}{K_m + C}$. This describes the clearance of dopamine from the extracellular space.\n\n**2. Cocaine Condition**\n-   **Mechanism:** Cocaine is a competitive inhibitor, so the uptake function changes to $U'(C) = \\frac{V_{\\max}C}{K_m' + C}$, where $K_m' = K_m(1 + [I]/K_i) > K_m$. The vesicular release $R_{\\mathrm{ves}}(t)$ is unchanged for a given stimulus, and $J_{\\mathrm{rev}} \\approx 0$.\n-   **Baseline:** The steady-state equation is $\\frac{dC}{dt} = 0 + 0 - U'(C) = 0$, which again implies $C_{ss} = 0$. The baseline remains near zero.\n-   **Evoked Transient:**\n    -   **Peak:** During release, the net rate of change is $\\frac{dC}{dt} = R_{\\mathrm{ves}}(t) - U'(C)$. Since $K_m' > K_m$, we have $U'(C) < U(C)$ for any $C>0$. The clearance is inhibited. With the same release $R_{\\mathrm{ves}}(t)$ but reduced clearance, dopamine accumulates to a higher concentration, resulting in a **larger peak**.\n    -   **Decay:** The decay phase is governed by $\\frac{dC}{dt} = -U'(C)$. Since the clearance rate $U'(C)$ is smaller than in the control case, the decay will be **slower**.\n    -   **Area Under the Curve (AUC):** A larger peak and slower decay necessarily lead to an increased AUC, reflecting the prolonged presence of dopamine in the extracellular space.\n\n**3. Amphetamine Condition**\n-   **Mechanism:** Amphetamine increases tonic efflux ($J_{\\mathrm{rev}} > 0$), reduces evoked release ($R_{\\mathrm{ves}}(t)$ amplitude is smaller), and competes for uptake, which slows net dopamine clearance. Let's call the modified uptake function $U''(C)$.\n-   **Baseline:** The steady-state equation is $\\frac{dC}{dt} = J_{\\mathrm{rev}} - U''(C_{ss}) = 0$. Since $J_{\\mathrm{rev}} > 0$, it must be that $U''(C_{ss}) > 0$, which requires a non-zero steady-state concentration $C_{ss} > 0$. Therefore, amphetamine causes a **tonic elevation of baseline extracellular dopamine**.\n-   **FSCV Signal:** Crucially, FSCV with background subtraction measures phasic changes *relative to the local baseline*. The elevated tonic level $C_{ss}$ becomes the new \"zero\" for the measurement.\n-   **Evoked Transient:**\n    -   **Peak:** The stimulus evokes a smaller release $R_{\\mathrm{ves}}(t)$ than in control due to depletion of vesicular stores. The FSCV signal measures the deviation from the elevated baseline $C_{ss}$. Since the amount of dopamine released is smaller, the **evoked peak relative to baseline is reduced**. The problem statement correctly notes this effect can be progressive with repeated stimulation.\n    -   **Decay:** The decay of the phasic signal represents the return of $C(t)$ to the new steady-state level $C_{ss}$. This process is governed by the dynamics around $C_{ss}$. Amphetamine competes with dopamine for DAT, inhibiting dopamine's own clearance. This impairment of the clearance mechanism means the decay of the phasically-released dopamine back to baseline will be **slower**, and the overall transient will appear broadened.\n\n### Option-by-Option Analysis\n-   **A. Cocaine: baseline extracellular dopamine remains near zero between stimuli, the evoked peak is larger and the decay is slower, increasing the area under the curve. Amphetamine: the baseline extracellular dopamine is elevated prior to stimulation, the evoked peak relative to baseline is reduced and can progressively diminish with repeated stimuli, and the decay is slower with a broadened transient.**\n    -   This option perfectly matches the derived effects for both drugs. The description for cocaine (zero baseline, larger peak, slower decay) and amphetamine (elevated true baseline, reduced phasic peak in FSCV, slower decay) is fully consistent with the model.\n    -   **Verdict: Correct**\n\n-   **B. Cocaine: baseline extracellular dopamine shows a marked tonic elevation due to increased non-vesicular release, the evoked peak is reduced, and the decay is faster. Amphetamine: baseline remains near zero, the evoked peak is larger due to uptake inhibition, and the decay is unchanged.**\n    -   The description for cocaine is incorrect; it does not increase $J_{\\mathrm{rev}}$ and thus does not elevate baseline. It increases the peak, not reduces it, and slows decay, not fastens it. The description for amphetamine is incorrect; it elevates baseline, does not leave it near zero. It reduces the evoked peak, not increases it.\n    -   **Verdict: Incorrect**\n\n-   **C. Cocaine: because uptake becomes saturated, the evoked transient decays faster to baseline with a smaller area under the curve, while baseline remains near zero. Amphetamine: reverse transport has no effect on baseline, but the evoked peak is greatly increased with a faster decay due to transporter cycling.**\n    -   The description for cocaine is incorrect. Competitive inhibition (increased $K_m'$) actually makes the transporter *less* prone to saturation at a given concentration and slows decay, not speeds it up. The description for amphetamine is incorrect; reverse transport ($J_{\\mathrm{rev}} > 0$) is the direct cause of baseline elevation.\n    -   **Verdict: Incorrect**\n\n-   **D. Cocaine: uptake inhibition prolongs the rise time, yielding a slower and smaller peak with no change in decay, and it elevates baseline substantially. Amphetamine: reverse transport accelerates clearance, shortening the decay time, and it increases the evoked peak amplitude because more dopamine is expelled during exocytosis.**\n    -   The description for cocaine is incorrect on multiple counts: the peak is larger (not smaller), the decay is slower (not unchanged), and the baseline is not elevated. The description for amphetamine is also incorrect: it slows (not accelerates) net clearance and reduces (not increases) the evoked release amplitude.\n    -   **Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "2728176"}, {"introduction": "Once a drug elevates dopamine levels, the postsynaptic neuron must interpret this signal to initiate a cellular response. This exercise focuses on a crucial node in this process: the activation of Protein Kinase A (PKA) by its second messenger, cyclic AMP ($cAMP$), following D1 receptor stimulation. By deriving and applying the Hill equation, you will explore the biophysical principle of cooperativity, which allows signaling molecules to function as highly sensitive molecular switches in response to changing inputs. [@problem_id:2728192]", "problem": "In medium spiny neurons of the nucleus accumbens expressing dopamine D1 receptors, phasic dopamine release activates adenylyl cyclase to elevate cyclic adenosine monophosphate (cAMP), which promotes release of the catalytic subunits of protein kinase A (PKA) from the regulatory subunits. Consider a steady-state episode in which intracellular cAMP reaches $5\\ \\mu\\text{M}$. The regulatory moiety of the PKA holoenzyme exhibits cooperative activation by cAMP that can be captured by a Hill relation characterized by an apparent equilibrium dissociation constant $K_{d}$ and a Hill coefficient $n$. Assume $K_{d}=1\\ \\mu\\text{M}$ and $n=2$ for the effective activation process.\n\nUsing only the definition of the Hill relation for cooperative binding, where the Hill coefficient $n$ is the slope of the Hill plot $\\log\\!\\left(\\frac{f}{1-f}\\right)$ versus $\\log(c)$ and $K_{d}$ is the ligand concentration $c$ at which the fractional activation $f$ equals $1/2$, first derive an expression for the fractional activation $f$ of PKA as a function of the cAMP concentration $c$, $K_{d}$, and $n$. Then, evaluate $f$ at $c=5\\ \\mu\\text{M}$ with the given parameters. Express your final numerical result as a reduced fraction with no units. No rounding is required.", "solution": "The problem requires the derivation of the fractional activation of protein kinase A (PKA), denoted by $f$, as a function of the concentration of cyclic adenosine monophosphate (cAMP), $c$. The derivation must be based on the provided partial definition of the Hill relation. Following the derivation, the value of $f$ must be calculated for the given parameters.\n\nFirst, we address the derivation. The problem states that the Hill coefficient, $n$, is the slope of a Hill plot, which is a graph of $\\log\\left(\\frac{f}{1-f}\\right)$ versus $\\log(c)$. This relationship can be expressed as a linear equation:\n$$ \\log\\left(\\frac{f}{1-f}\\right) = n \\log(c) + b $$\nwhere $b$ is the intercept on the $\\log\\left(\\frac{f}{1-f}\\right)$ axis. The base of the logarithm is arbitrary and does not affect the final form of the relationship.\n\nTo determine the intercept $b$, we use the second piece of information provided: the apparent equilibrium dissociation constant, $K_{d}$, is the ligand concentration $c$ at which the fractional activation $f$ is equal to $1/2$. We substitute $c=K_d$ and $f=1/2$ into the linear equation:\n$$ \\log\\left(\\frac{1/2}{1 - 1/2}\\right) = n \\log(K_d) + b $$\n$$ \\log\\left(\\frac{1/2}{1/2}\\right) = n \\log(K_d) + b $$\n$$ \\log(1) = n \\log(K_d) + b $$\nSince $\\log(1) = 0$ for any base, we find the intercept $b$:\n$$ 0 = n \\log(K_d) + b \\implies b = -n \\log(K_d) $$\nNow, we substitute the expression for $b$ back into the original linear equation:\n$$ \\log\\left(\\frac{f}{1-f}\\right) = n \\log(c) - n \\log(K_d) $$\nUsing the property of logarithms $\\log(x) - \\log(y) = \\log(x/y)$, we can combine the terms on the right side:\n$$ \\log\\left(\\frac{f}{1-f}\\right) = n \\left(\\log(c) - \\log(K_d)\\right) = n \\log\\left(\\frac{c}{K_d}\\right) $$\nUsing the property $n \\log(x) = \\log(x^n)$, we have:\n$$ \\log\\left(\\frac{f}{1-f}\\right) = \\log\\left(\\left(\\frac{c}{K_d}\\right)^n\\right) $$\nFor the logarithms to be equal, their arguments must be equal. Therefore, we can remove the logarithm from both sides:\n$$ \\frac{f}{1-f} = \\left(\\frac{c}{K_d}\\right)^n $$\nThis is the Hill equation. The final step of the derivation is to solve this equation for $f$:\n$$ f = (1-f) \\left(\\frac{c}{K_d}\\right)^n $$\n$$ f = \\left(\\frac{c}{K_d}\\right)^n - f \\left(\\frac{c}{K_d}\\right)^n $$\n$$ f + f \\left(\\frac{c}{K_d}\\right)^n = \\left(\\frac{c}{K_d}\\right)^n $$\n$$ f \\left(1 + \\left(\\frac{c}{K_d}\\right)^n\\right) = \\left(\\frac{c}{K_d}\\right)^n $$\n$$ f = \\frac{\\left(\\frac{c}{K_d}\\right)^n}{1 + \\left(\\frac{c}{K_d}\\right)^n} $$\nTo express this in a more standard form, we can multiply the numerator and the denominator by $K_d^n$:\n$$ f(c; K_d, n) = \\frac{c^n}{K_d^n + c^n} $$\nThis is the required expression for the fractional activation $f$ of PKA.\n\nSecond, we evaluate $f$ using the provided parameter values:\n- cAMP concentration, $c = 5\\ \\mu\\text{M}$\n- Apparent equilibrium dissociation constant, $K_{d} = 1\\ \\mu\\text{M}$\n- Hill coefficient, $n = 2$\n\nSubstituting these values into the derived expression:\n$$ f = \\frac{(5\\ \\mu\\text{M})^2}{(1\\ \\mu\\text{M})^2 + (5\\ \\mu\\text{M})^2} $$\nThe units $(\\mu\\text{M})^2$ cancel out, as is required for a dimensionless fractional quantity.\n$$ f = \\frac{5^2}{1^2 + 5^2} = \\frac{25}{1 + 25} = \\frac{25}{26} $$\nThe integers $25$ and $26$ are coprime, so the fraction $\\frac{25}{26}$ is in its most reduced form.", "answer": "$$\\boxed{\\frac{25}{26}}$$", "id": "2728192"}, {"introduction": "The development of a stable addictive state involves long-lasting molecular adaptations that create a form of cellular memory. This final practice examines the accumulation of the transcription factor ΔFosB, a famously stable protein that acts as a master regulator of these persistent changes. Using a fundamental model of protein turnover based on first-order kinetics, you will demonstrate quantitatively how increasing a protein's stability, rather than its synthesis rate, serves as a powerful mechanism for its accumulation during chronic drug exposure. [@problem_id:2728200]", "problem": "In the striatal medium spiny neuron, the transcription factor $\\Delta\\text{FosB}$ accumulates under chronic drug exposure due in part to post-translational stabilization that increases its half-life. Consider a coarse-grained model in which the nuclear concentration $x(t) \\equiv [\\Delta\\text{FosB}](t)$ evolves according to first-order synthesis and degradation with constant mean synthesis rate $s$ (in concentration units per unit time) and first-order degradation rate constant $\\lambda$ (in inverse time), so that $x(t)$ obeys the linear ordinary differential equation\n$$\n\\frac{dx}{dt} = s - \\lambda x,\n$$\nwith initial condition $x(0) = 0$ reflecting negligible initial accumulation.\n\nStarting from well-tested biochemical kinetics facts that (i) protein degradation following a memoryless decay is first-order with rate constant $\\lambda$ and (ii) the half-life $t_{1/2}$ is related to $\\lambda$ by $\\lambda = \\frac{\\ln 2}{t_{1/2}}$, perform the following steps:\n\n1. Solve the differential equation for $x(t)$ in closed form for arbitrary constant $s$ and $\\lambda$ and the stated initial condition.\n2. From your solution, identify the steady-state concentration $x_{\\ast}$ as a function of $s$ and $\\lambda$.\n3. Define the fold-change in steady-state $\\mathcal{F}$ under chronic exposure that stabilizes $\\Delta\\text{FosB}$ (reduces $\\lambda$) relative to acute exposure (baseline $\\lambda$) by\n$$\n\\mathcal{F} \\equiv \\frac{x_{\\ast}^{(\\text{chronic})}}{x_{\\ast}^{(\\text{acute})}}.\n$$\nExpress $\\mathcal{F}$ in terms of the corresponding half-lives $t_{1/2}^{(\\text{acute})}$ and $t_{1/2}^{(\\text{chronic})}$, assuming the mean synthesis rate $s$ is unchanged between conditions.\n4. Finally, evaluate $\\mathcal{F}$ for $t_{1/2}^{(\\text{acute})} = 12\\,\\text{h}$ and $t_{1/2}^{(\\text{chronic})} = 96\\,\\text{h}$. Report the single numerical value of $\\mathcal{F}$, rounded to three significant figures. The final answer is dimensionless; do not include units in the final numerical value.", "solution": "The problem statement is first subjected to rigorous validation.\n\nThe givens are as follows:\n1.  The differential equation for the concentration $x(t)$ of $\\Delta\\text{FosB}$: $\\frac{dx}{dt} = s - \\lambda x$.\n2.  The initial condition: $x(0) = 0$.\n3.  The relationship between the degradation rate constant $\\lambda$ and half-life $t_{1/2}$: $\\lambda = \\frac{\\ln 2}{t_{1/2}}$.\n4.  The definition of the fold-change in steady-state concentration: $\\mathcal{F} \\equiv \\frac{x_{\\ast}^{(\\text{chronic})}}{x_{\\ast}^{(\\text{acute})}}$.\n5.  The assumption that the synthesis rate $s$ is constant between acute and chronic conditions.\n6.  The specific values for half-lives: $t_{1/2}^{(\\text{acute})} = 12\\,\\text{h}$ and $t_{1/2}^{(\\text{chronic})} = 96\\,\\text{h}$.\n\nThe problem is deemed valid. It is scientifically grounded, employing a standard first-order kinetic model fundamental to chemical kinetics and pharmacology. The biological context is realistic. The problem is well-posed: it is a linear first-order ordinary differential equation with a specified initial condition, which guarantees a unique and stable solution. All terms are precisely defined, and the given information is complete, consistent, and sufficient to perform the required calculations. The problem is a substantive exercise in mathematical modeling, not a triviality.\n\nThe solution proceeds in the requested steps.\n\nStep 1: Solve the differential equation for $x(t)$.\nThe governing equation is a linear first-order non-homogeneous ordinary differential equation:\n$$\n\\frac{dx}{dt} + \\lambda x = s\n$$\nTo solve this, we use the method of integrating factors. The integrating factor is $I(t) = \\exp\\left(\\int \\lambda \\,dt\\right) = \\exp(\\lambda t)$. Multiplying the equation by $I(t)$ yields:\n$$\n\\exp(\\lambda t) \\frac{dx}{dt} + \\lambda \\exp(\\lambda t) x = s \\exp(\\lambda t)\n$$\nThe left-hand side is the derivative of the product $x(t) \\exp(\\lambda t)$ with respect to $t$, according to the product rule:\n$$\n\\frac{d}{dt}\\left(x(t) \\exp(\\lambda t)\\right) = s \\exp(\\lambda t)\n$$\nIntegrating both sides with respect to $t$:\n$$\n\\int \\frac{d}{dt}\\left(x(t) \\exp(\\lambda t)\\right) dt = \\int s \\exp(\\lambda t) dt\n$$\n$$\nx(t) \\exp(\\lambda t) = \\frac{s}{\\lambda} \\exp(\\lambda t) + C\n$$\nwhere $C$ is the constant of integration. Dividing by $\\exp(\\lambda t)$ gives the general solution for $x(t)$:\n$$\nx(t) = \\frac{s}{\\lambda} + C \\exp(-\\lambda t)\n$$\nWe apply the initial condition $x(0) = 0$ to determine the constant $C$:\n$$\nx(0) = 0 = \\frac{s}{\\lambda} + C \\exp(-\\lambda \\cdot 0) = \\frac{s}{\\lambda} + C\n$$\nThis implies $C = -\\frac{s}{\\lambda}$. Substituting this value of $C$ back into the general solution gives the particular solution:\n$$\nx(t) = \\frac{s}{\\lambda} - \\frac{s}{\\lambda} \\exp(-\\lambda t) = \\frac{s}{\\lambda} \\left(1 - \\exp(-\\lambda t)\\right)\n$$\n\nStep 2: Identify the steady-state concentration $x_{\\ast}$.\nThe steady-state concentration $x_{\\ast}$ is the value of $x(t)$ as time approaches infinity, $t \\to \\infty$. Since $\\lambda > 0$ for a degradation process, the term $\\exp(-\\lambda t)$ approaches $0$ as $t \\to \\infty$.\n$$\nx_{\\ast} = \\lim_{t \\to \\infty} x(t) = \\lim_{t \\to \\infty} \\left[\\frac{s}{\\lambda} \\left(1 - \\exp(-\\lambda t)\\right)\\right] = \\frac{s}{\\lambda} (1 - 0) = \\frac{s}{\\lambda}\n$$\nThus, the steady-state concentration is $x_{\\ast} = \\frac{s}{\\lambda}$.\n\nStep 3: Express the fold-change $\\mathcal{F}$ in terms of half-lives.\nThe fold-change $\\mathcal{F}$ is defined as the ratio of the steady-state concentrations under chronic and acute exposure conditions:\n$$\n\\mathcal{F} = \\frac{x_{\\ast}^{(\\text{chronic})}}{x_{\\ast}^{(\\text{acute})}}\n$$\nUsing the expression for $x_{\\ast}$ from Step 2, we have:\n$$\nx_{\\ast}^{(\\text{chronic})} = \\frac{s}{\\lambda_{\\text{chronic}}} \\quad \\text{and} \\quad x_{\\ast}^{(\\text{acute})} = \\frac{s}{\\lambda_{\\text{acute}}}\n$$\nThe synthesis rate $s$ is assumed to be the same in both conditions. Substituting these expressions into the formula for $\\mathcal{F}$:\n$$\n\\mathcal{F} = \\frac{s / \\lambda_{\\text{chronic}}}{s / \\lambda_{\\text{acute}}} = \\frac{\\lambda_{\\text{acute}}}{\\lambda_{\\text{chronic}}}\n$$\nNow, we use the provided relationship between the rate constant $\\lambda$ and the half-life $t_{1/2}$, which is $\\lambda = \\frac{\\ln 2}{t_{1/2}}$. We substitute this into our expression for $\\mathcal{F}$:\n$$\n\\mathcal{F} = \\frac{\\frac{\\ln 2}{t_{1/2}^{(\\text{acute})}}}{\\frac{\\ln 2}{t_{1/2}^{(\\text{chronic})}}}\n$$\nThe factor $\\ln 2$ cancels, leaving a simple ratio of the half-lives:\n$$\n\\mathcal{F} = \\frac{t_{1/2}^{(\\text{chronic})}}{t_{1/2}^{(\\text{acute})}}\n$$\n\nStep 4: Evaluate $\\mathcal{F}$ for the given numerical values.\nThe problem provides the half-lives: $t_{1/2}^{(\\text{acute})} = 12\\,\\text{h}$ and $t_{1/2}^{(\\text{chronic})} = 96\\,\\text{h}$. Substituting these values into the expression for $\\mathcal{F}$:\n$$\n\\mathcal{F} = \\frac{96}{12} = 8\n$$\nThe problem requires the answer to be rounded to three significant figures. The exact value is $8$. To express this with three significant figures, we write it as a decimal.\n$$\n\\mathcal{F} = 8.00\n$$", "answer": "$$\\boxed{8.00}$$", "id": "2728200"}]}